메뉴 건너뛰기




Volumn 106, Issue 2, 2011, Pages 265-271

Clopidogrel response variability and the advent of personalized antiplatelet therapy: A bench to bedside journey

Author keywords

Adp receptors; Antiplatelet drugs; Atherothrombosis; Clinical trials

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

EID: 79961049388     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-03-0167     Document Type: Review
Times cited : (32)

References (69)
  • 1
    • 0032738817 scopus 로고    scopus 로고
    • Stable versus unstable atherosclerosis: Clinical aspects
    • Falk E. Stable versus unstable atherosclerosis: clinical aspects. Am Heart J 1999; 138: S421-425.
    • (1999) Am Heart J , vol.138
    • Falk, E.1
  • 2
    • 0034573839 scopus 로고    scopus 로고
    • Pathophysiological insights from studies of retrieved coronary atherectomy tissue
    • Glover C, O'Brien ER. Pathophysiological insights from studies of retrieved coronary atherectomy tissue. Semin Interv Cardiol 2000; 5: 167-173.
    • (2000) Semin Interv Cardiol , vol.5 , pp. 167-173
    • Glover, C.1    O'Brien, E.R.2
  • 3
    • 0017723098 scopus 로고
    • Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerosis patients and its prevention
    • Sano T, Motomiya T, Yamazaki H, et al. Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerosis patients and its prevention. Thromb Haemost 1977; 37: 329-338.
    • (1977) Thromb Haemost , vol.37 , pp. 329-338
    • Sano, T.1    Motomiya, T.2    Yamazaki, H.3
  • 4
    • 0019504566 scopus 로고
    • Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease
    • Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691.
    • (1981) N Engl J Med , vol.304 , pp. 685-691
    • Hirsh, P.D.1    Hillis, L.D.2    Campbell, W.B.3
  • 6
    • 0025280866 scopus 로고
    • Platelet hyperreactivity and prognosis in survivors of myocardial infarction
    • Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
    • (1990) N Engl J Med , vol.322 , pp. 1549-1554
    • Trip, M.D.1    Cats, V.M.2    van Capelle, F.J.3
  • 7
    • 0023160207 scopus 로고
    • Hyperactive platelets and complications of coronary artery disease
    • Hirsh J. Hyperactive platelets and complications of coronary artery disease. N Engl J Med 1987; 316: 1543-1544.
    • (1987) N Engl J Med , vol.316 , pp. 1543-1544
    • Hirsh, J.1
  • 8
    • 33646568098 scopus 로고    scopus 로고
    • Antiplatelet therapy: Current strategies and future trends
    • Tantry US, Etherington A, Bliden KP, et al. Antiplatelet therapy: current strategies and future trends. Future Cardiol 2006; 2: 343-366.
    • (2006) Future Cardiol , vol.2 , pp. 343-366
    • Tantry, U.S.1    Etherington, A.2    Bliden, K.P.3
  • 9
    • 0030053912 scopus 로고    scopus 로고
    • Platelet function in acute myocardial infarction treated with direct angioplasty
    • Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
    • (1996) Circulation , vol.93 , pp. 229-237
    • Gawaz, M.1    Neumann, F.J.2    Ott, I.3
  • 10
    • 27744444421 scopus 로고    scopus 로고
    • Resistance to antiplatelet drugs: Current status and future research
    • Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005; 6: 2027-2045.
    • (2005) Expert Opin Pharmacother , vol.6 , pp. 2027-2045
    • Tantry, U.S.1    Bliden, K.P.2    Gurbel, P.A.3
  • 11
    • 85047693299 scopus 로고    scopus 로고
    • Central role of the P2Y12 receptor in platelet activation
    • Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
    • (2004) J Clin Invest , vol.113 , pp. 340-345
    • Dorsam, R.T.1    Kunapuli, S.P.2
  • 12
    • 33847254554 scopus 로고    scopus 로고
    • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting
    • Gurbel PA, Bliden KP, Guyer K, et al. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007; 119: 563-570.
    • (2007) Thromb Res , vol.119 , pp. 563-570
    • Gurbel, P.A.1    Bliden, K.P.2    Guyer, K.3
  • 13
    • 84856051204 scopus 로고    scopus 로고
    • Differential effects of clopidogrel on platelet activation measured by annexin binding vs. platelet aggregation: An explanation for rapid antithrombotic properties even in the presence of clopidogrel "resistance"
    • Gurbel PA, Bliden K, Antonino M, et al. Differential Effects of Clopidogrel on Platelet Activation Measured by Annexin Binding vs. Platelet Aggregation: An Explanation for Rapid Antithrombotic Properties Even in the Presence of Clopidogrel "Resistance" Circulation 2010; 122: A19956.
    • (2010) Circulation , vol.122
    • Gurbel, P.A.1    Bliden, K.2    Antonino, M.3
  • 14
    • 31344456454 scopus 로고    scopus 로고
    • Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting
    • Yip HK, Chang LT, Sun CK, et al. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 2006; 97: 192-194.
    • (2006) Am J Cardiol , vol.97 , pp. 192-194
    • Yip, H.K.1    Chang, L.T.2    Sun, C.K.3
  • 15
    • 33646561025 scopus 로고    scopus 로고
    • Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: Results from the CLEAR PLATELETS 1b study
    • Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006; 48: 2186-2191.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 2186-2191
    • Gurbel, P.A.1    Bliden, K.P.2    Tantry, U.S.3
  • 16
    • 3242693541 scopus 로고    scopus 로고
    • Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    • Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360.
    • (2004) Am J Cardiol , vol.94 , pp. 358-360
    • Vivekananthan, D.P.1    Bhatt, D.L.2    Chew, D.P.3
  • 17
    • 0034691260 scopus 로고    scopus 로고
    • Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
    • Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-2828.
    • (2000) Circulation , vol.101 , pp. 2823-2828
    • Cadroy, Y.1    Bossavy, J.P.2    Thalamas, C.3
  • 18
    • 0032170080 scopus 로고    scopus 로고
    • A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans
    • Bossavy JP, Thalamas C, Sagnard L, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92: 1518-1525.
    • (1998) Blood , vol.92 , pp. 1518-1525
    • Bossavy, J.P.1    Thalamas, C.2    Sagnard, L.3
  • 19
    • 0036379817 scopus 로고    scopus 로고
    • Individual variations of platelet inhibition after loading doses of clopidogrel
    • Järemo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
    • (2002) J Intern Med , vol.252 , pp. 233-238
    • Järemo, P.1    Lindahl, T.L.2    Fransson, S.G.3
  • 20
    • 0036679656 scopus 로고    scopus 로고
    • Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation
    • Gurbel PA, Malinin AI, Callahan KP, et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol 2002; 90: 312-315.
    • (2002) Am J Cardiol , vol.90 , pp. 312-315
    • Gurbel, P.A.1    Malinin, A.I.2    Callahan, K.P.3
  • 21
    • 0037326063 scopus 로고    scopus 로고
    • Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial
    • nset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial
    • Gurbel PA, Cummings CC, Bell CR, et al.; Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145: 239-247.
    • (2003) Am Heart J , vol.145 , pp. 239-247
    • Gurbel, P.A.1    Cummings, C.C.2    Bell, C.R.3
  • 22
    • 0038649988 scopus 로고    scopus 로고
    • Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
    • Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    • (2003) Circulation , vol.107 , pp. 2908-2913
    • Gurbel, P.A.1    Bliden, K.P.2    Hiatt, B.L.3    O'Connor, C.M.4
  • 23
    • 77953911457 scopus 로고    scopus 로고
    • Working Group on High On-Treatment Platelet Reactivity
    • Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate
    • Bonello L, Tantry US, Marcucci R, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 919-933
    • Bonello, L.1    Tantry, U.S.2    Marcucci, R.3
  • 24
    • 0038291914 scopus 로고    scopus 로고
    • Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement
    • Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
    • (2003) Thromb Haemost , vol.89 , pp. 783-787
    • Müller, I.1    Besta, F.2    Schulz, C.3
  • 25
    • 77955449383 scopus 로고    scopus 로고
    • Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients
    • Paniccia R, Antonucci E, Maggini N, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292.
    • (2010) Thromb Haemost , vol.104 , pp. 287-292
    • Paniccia, R.1    Antonucci, E.2    Maggini, N.3
  • 26
    • 62449095155 scopus 로고    scopus 로고
    • Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation
    • Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
    • (2009) Thromb Haemost , vol.101 , pp. 333-339
    • Gremmel, T.1    Steiner, S.2    Seidinger, D.3
  • 27
    • 0038354521 scopus 로고    scopus 로고
    • Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator6stimulated phosphoprotein phosphorylation
    • Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator6stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
    • (2003) Catheter Cardiovasc Interv , vol.59 , pp. 295-302
    • Barragan, P.1    Bouvier, J.L.2    Roquebert, P.O.3
  • 28
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1    Shenkman, B.2    Guetta, V.3
  • 29
    • 9644281093 scopus 로고    scopus 로고
    • The difference between clopidogrel responsiveness and posttreatment platelet reactivity
    • Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 89-94.
    • (2005) Thromb Res , vol.115 , pp. 89-94
    • Samara, W.M.1    Bliden, K.P.2    Tantry, U.S.3
  • 30
    • 27644536235 scopus 로고    scopus 로고
    • Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POSTSTENTING Study
    • Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1820-1826
    • Gurbel, P.A.1    Bliden, K.P.2    Guyer, K.3
  • 31
    • 14944378655 scopus 로고    scopus 로고
    • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
    • Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005; 111: 1153-1159.
    • (2005) Circulation , vol.111 , pp. 1153-1159
    • Gurbel, P.A.1    Bliden, K.P.2    Zaman, K.A.3
  • 32
    • 74249104162 scopus 로고    scopus 로고
    • Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting
    • Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
    • (2010) Thromb Haemost , vol.103 , pp. 151-159
    • Sibbing, D.1    Morath, T.2    Braun, S.3
  • 33
    • 77952075376 scopus 로고    scopus 로고
    • Clopidogrelnon-responsiveness and risk of cardiovascular morbidity
    • An updated meta-analysis
    • Sofi F, Marcucci R, Gori AM, et al. Clopidogrelnon-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
    • (2010) Thromb Haemost , vol.103 , pp. 841-848
    • Sofi, F.1    Marcucci, R.2    Gori, A.M.3
  • 34
    • 27644465874 scopus 로고    scopus 로고
    • The clopidogrel Resistance and Stent Thrombosis (CREST) study
    • Gurbel PA, Bliden KP, Samara W, et al. The clopidogrel Resistance and Stent Thrombosis (CREST) study. J Am Coll Cardiol 2005; 46: 1827-1832.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 1827-1832
    • Gurbel, P.A.1    Bliden, K.P.2    Samara, W.3
  • 35
    • 33846837282 scopus 로고    scopus 로고
    • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
    • Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 657-666
    • Bliden, K.P.1    Dichiara, J.2    Tantry, U.S.3
  • 36
    • 74749097435 scopus 로고    scopus 로고
    • Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
    • Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
    • (2010) J Thromb Haemost , vol.8 , pp. 250-256
    • Sibbing, D.1    Schulz, S.2    Braun, S.3
  • 37
    • 79952598836 scopus 로고    scopus 로고
    • GRAVITAS Investigators
    • Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
    • Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
    • (2011) J Am Med Assoc , vol.305 , pp. 1097-1105
    • Price, M.J.1    Berger, P.B.2    Teirstein, P.S.3
  • 38
    • 77249113768 scopus 로고    scopus 로고
    • Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    • Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
    • (2010) J Am Med Assoc , vol.303 , pp. 754-762
    • Breet, N.J.1    van Werkum, J.W.2    Bouman, H.J.3
  • 39
    • 79961092373 scopus 로고    scopus 로고
    • Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks
    • Gurbel PA, Mahla E, Tantry US. Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Thromb Haemost 2011; 106: 248-252.
    • (2011) Thromb Haemost , vol.106 , pp. 248-252
    • Gurbel, P.A.1    Mahla, E.2    Tantry, U.S.3
  • 40
    • 36949000480 scopus 로고    scopus 로고
    • The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis
    • Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
    • (2007) Thromb Haemost , vol.98 , pp. 1329-1334
    • Blindt, R.1    Stellbrink, K.2    de Taeye, A.3
  • 41
    • 35048856897 scopus 로고    scopus 로고
    • ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome
    • Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non- ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
    • (2007) Thromb Haemost , vol.98 , pp. 838-843
    • Frere, C.1    Cuisset, T.2    Quilici, J.3
  • 42
    • 44949173754 scopus 로고    scopus 로고
    • Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    • Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
    • (2008) Eur Heart J , vol.29 , pp. 992-1000
    • Price, M.J.1    Endemann, S.2    Gollapudi, R.R.3
  • 43
    • 56549090507 scopus 로고    scopus 로고
    • Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target
    • Gurbel PA, Antonino MJ, Bliden KP, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19: 595-604.
    • (2008) Platelets , vol.19 , pp. 595-604
    • Gurbel, P.A.1    Antonino, M.J.2    Bliden, K.P.3
  • 44
    • 34447636769 scopus 로고    scopus 로고
    • Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to Percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
    • Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to Percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636.
    • (2007) J Thromb Haemost , vol.5 , pp. 1630-1636
    • Bonello, L.1    Paganelli, F.2    Arpin-Bornet, M.3
  • 45
    • 59849120163 scopus 로고    scopus 로고
    • Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
    • Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-342.
    • (2009) Circulation , vol.119 , pp. 237-342
    • Marcucci, R.1    Gori, A.M.2    Paniccia, R.3
  • 46
    • 60949083948 scopus 로고    scopus 로고
    • Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    • Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 849-856
    • Sibbing, D.1    Braun, S.2    Morath, T.3
  • 47
    • 70349510067 scopus 로고    scopus 로고
    • Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients
    • Cuisset T, Frere C, Quilici J, et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009; 104: 1078-1082.
    • (2009) Am J Cardiol , vol.104 , pp. 1078-1082
    • Cuisset, T.1    Frere, C.2    Quilici, J.3
  • 48
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
    • Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1404-1411
    • Bonello, L.1    Camoin-Jau, L.2    Arques, S.3
  • 49
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
    • (2009) Am J Cardiol , vol.103 , pp. 5-10
    • Bonello, L.1    Camoin-Jau, L.2    Armero, S.3
  • 50
    • 67650745975 scopus 로고    scopus 로고
    • on behalf of tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3t/2r) investigators
    • Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study
    • Valgimigli M, Campo G, de Cesare N, et al., on behalf of Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-3222.
    • (2009) Circulation , vol.119 , pp. 3215-3222
    • Valgimigli, M.1    Campo, G.2    de Cesare, N.3
  • 51
    • 57549099501 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: A prospective, randomized study
    • Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. J Am Coll Cardiol Intv 2008; 1: 649-653.
    • (2008) J Am Coll Cardiol Intv , vol.1 , pp. 649-653
    • Cuisset, T.1    Frere, C.2    Quilici, J.3
  • 52
    • 79952611488 scopus 로고    scopus 로고
    • An initial experiment with personalized antiplatelet therapy: The GRAVITAS trial
    • Gurbel PA, Tantry US. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. J Am Med Assoc 2011; 305: 1136-1137.
    • (2011) J Am Med Assoc , vol.305 , pp. 1136-1137
    • Gurbel, P.A.1    Tantry, U.S.2
  • 54
    • 84856053185 scopus 로고    scopus 로고
    • TRIGGER-PCI halted: Low events stymie platelet-reactivity trial with prasugrel, clopidogrel, Accessed on 4-28-2011
    • TRIGGER-PCI halted: Low events stymie platelet-reactivity trial with prasugrel, clopidogrel (http://www.theheart.org/article/1200057.do). Accessed on 4-28-2011.
  • 55
    • 79955110460 scopus 로고    scopus 로고
    • Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High- Dose (150-mg) Clopidogrel The Importance of CYP2C19 2 Genotyping
    • Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High- Dose (150-mg) Clopidogrel The Importance of CYP2C19 2 Genotyping. JACC Cardiovasc Interv 2011; 4: 403-410.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 403-410
    • Alexopoulos, D.1    Dimitropoulos, G.2    Davlouros, P.3
  • 56
    • 77955690680 scopus 로고    scopus 로고
    • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/ non-ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
    • e1
    • Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/ non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16-22.e1.
    • (2010) Am Heart J , vol.160 , pp. 16-22
    • Chin, C.T.1    Roe, M.T.2    Fox, K.A.3
  • 57
    • 77749289646 scopus 로고    scopus 로고
    • Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies
    • Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.
    • (2010) Thromb Haemost , vol.103 , pp. 535-544
    • Becker, R.C.1    Gurbel, P.A.2
  • 58
    • 70349863391 scopus 로고    scopus 로고
    • Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis
    • van Giezen JJ, Berntsson P, Zachrisson H, et al. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009; 124: 565-571.
    • (2009) Thromb Res , vol.124 , pp. 565-571
    • van Giezen, J.J.1    Berntsson, P.2    Zachrisson, H.3
  • 59
    • 79957673659 scopus 로고    scopus 로고
    • The Influence of CYP2C19 Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Clinical Effectiveness of P2Y12 Inhibitors
    • Price MJ, Tantry US, Gurbel PA. The Influence of CYP2C19 Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Clinical Effectiveness of P2Y12 Inhibitors. Rev Cardiovasc Med 2011; 12: 1-12.
    • (2011) Rev Cardiovasc Med , vol.12 , pp. 1-12
    • Price, M.J.1    Tantry, U.S.2    Gurbel, P.A.3
  • 60
    • 77953896604 scopus 로고    scopus 로고
    • Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis
    • Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19 2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 134-143
    • Hulot, J.S.1    Collet, J.P.2    Silvain, J.3
  • 61
    • 78049326068 scopus 로고    scopus 로고
    • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci: A meta-analysis
    • Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci: A meta-analysis. J Am Med Assoc 2010; 304: 1821-1830.
    • (2010) J Am Med Assoc , vol.304 , pp. 1821-1830
    • Mega, J.L.1    Simon, T.2    Collet, J.P.3
  • 62
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
    • (2009) N Engl J Med , vol.360 , pp. 354-362
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 63
    • 66349133650 scopus 로고    scopus 로고
    • Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    • Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
    • (2009) Circulation , vol.119 , pp. 2553-2560
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 64
    • 77958100874 scopus 로고    scopus 로고
    • Effect of CYP2C19and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial
    • Wallentin L, James S, Storey RF, et al. Effect of CYP2C19and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the plato trial. Lancet 2010; 376: 1320-1328.
    • (2010) Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1    James, S.2    Storey, R.F.3
  • 65
    • 78049433100 scopus 로고    scopus 로고
    • Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    • Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363: 1704-1714.
    • (2010) N Engl J Med , vol.363 , pp. 1704-1714
    • Pare, G.1    Mehta, S.R.2    Yusuf, S.3
  • 67
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-518.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3
  • 68
    • 77958105401 scopus 로고    scopus 로고
    • Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON- TIMI 38 trial: A pharmacogenetic analysis
    • Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON- TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
    • (2010) Lancet , vol.376 , pp. 1312-1319
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3
  • 69
    • 78651239845 scopus 로고    scopus 로고
    • Paraoxonase-1 is a major determinant of clopidogrel efficacy
    • Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
    • (2011) Nat Med , vol.17 , pp. 110-116
    • Bouman, H.J.1    Schömig, E.2    van Werkum, J.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.